Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
3-V Bioscience-2640 · 1 trial · 1 indication
Subject undergoes a stable isotope infusion followed by blood draws. Plasma lipid samples are measured by gas chromatography/mass spectrophotometry.
| Arm | Type | Description |
|---|---|---|
| 3-V Bioscience-2640 | EXPERIMENTAL | Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days. |
| Name | Type | Description |
|---|---|---|
| 3-V Bioscience-2640 | DRUG | Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days. |
Inclusion Criteria: 1. Men with characteristics of metabolic syndrome 1. Waist circumference greater than 40 in (102 cm) 2. Plasma TG greater than 150 mg/dL 3. HDL cholesterol less than 40 mg/dL 4. Blood pressure greater than or equal to 130/85 mmHg 5. Fasting plasma glucose greater...
Top 3 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Orforglipron |
| Veru Inc | VERU | 1 | PHASE2 | Enobosarm |
3-V Bioscience-2640 is an investigational small molecule developed by Sagimet Biosciences Inc. for metabolic syndrome. It was studied in a Phase 1 clinical trial evaluating its ability to reduce de novo lipogenesis in subjects with characteristics of metabolic syndrome. The drug has completed one Phase 1 trial and is not approved for any indication.
3-V Bioscience-2640 was studied for metabolic syndrome, specifically to evaluate its effect on reducing de novo lipogenesis in subjects with characteristics of the condition. The research was conducted in a Phase 1 trial that has been completed. It is an investigational therapy and has not been approved for use in metabolic syndrome or any other indication.
3-V Bioscience-2640 is being developed by Sagimet Biosciences Inc., which trades under the ticker SGMT. The company is responsible for the clinical development of this investigational small molecule for metabolic syndrome.
3-V Bioscience-2640 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are currently no active trials. The drug remains investigational and has not received FDA approval for any indication.
3-V Bioscience-2640 has been evaluated in one completed Phase 1 clinical trial, NCT02948569, titled "Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome." The trial enrolled 12 participants in the United States and studied males aged 35 years and older.